CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 120 target
Drug / intervention
A1: SHR-A1811 +13 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05749588
NCT05749588Phase 2RecruitingOn TrackUpdated 2mo ago
Long Recruiting
CompareCT.gov

Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）

Fudan University·interventional·Posted Mar 1, 2023·Updated Apr 16, 2026

In Brief

A Phase 2 clinical trial evaluating A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab with famitinib, and 12 other interventions for Triple-negative Breast Cancer. Currently recruiting, targeting 120 participants across 1 site.

Detailed Summary

This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-negative Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
2023202420252026202720282029
First PostedMar 1, 2023
Enrollment StartMar 30, 2023
Primary CompletionDec 31, 2027
Study CompletionDec 31, 2028
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 3.3 years agoPrimary completion in 1.5 years

Interventions

A1: SHR-A1811drug

A1: an anti-HER2 antibody-drug conjugate (ADC)

A2: SHR-A1811 with Camrelizumab with famitinibdrug

A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) Camrelizumab: an anti-programmed death-1 (PD-1) antibody

B1: TROP2 ADCdrug

B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

B2: TROP2 ADC with Camrelizumabdrug

B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC Camrelizumab: an anti-programmed death-1 (PD-1) antibody

C1: SHR-A1811drug

C1: an anti-HER2 antibody-drug conjugate (ADC)

C2: SHR-A1811 with BP102drug

C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

D1: TROP2 ADCdrug

D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

D2: TROP2 ADC with BP102drug

D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

E1: SHR-A1811drug

E1: an anti-HER2 antibody-drug conjugate (ADC)

F1: TROP2 ADCdrug

F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

G1: SHR-A1811drug

G1: an anti-HER2 antibody-drug conjugate (ADC)

H1: TROP2 ADCdrug

H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

E2: SHR-A1811 with everolimusdrug

E1: SHR-A1811 an anti-HER2 antibody-drug conjugate (ADC) everolimus： an mTOR inhibitor

TQB2102 with TQB2868drug

TQB2102: an anti-HER2 antibody-drug conjugate (ADC) TQB2868: an anti-PD-1/TGF-β bispecific antibody in all-comer TNBC